Literature DB >> 28767195

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.

F Peyvandi1,2, M Makris3, P Collins4, D Lillicrap5, S W Pipe6, A Iorio7, F R Rosendaal8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28767195     DOI： 10.1111/jth.13762

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

1.  Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH.

Authors:  Barbara Konkle; Glen Pierce; Donna Coffin; Mayss Naccache; R Cary Clark; Lindsey George; Alfonso Iorio; Brian O'Mahony; Steven Pipe; Mark Skinner; Crystal Watson; Flora Peyvandi; Johnny Mahlangu
Journal:  J Thromb Haemost       Date:  2020-11       Impact factor: 5.824

2.  Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.

Authors:  Flora Peyvandi; Johnny N Mahlangu; Steven W Pipe; Charles R M Hay; Glenn F Pierce; Peter Kuebler; Rebecca Kruse-Jarres; Midori Shima
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

3.  Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.

Authors:  Flora Peyvandi; Karin Berger; Rainer Seitz; Anneliese Hilger; Marie-Laure Hecquet; Michael Wierer; Karl-Heinz Buchheit; Brian O'Mahony; Amanda Bok; Mike Makris; Ulrich Mansmann; Wolfgang Schramm; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-05-28       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.